Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995036 | 0.86 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL4150920 | 0.86 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL17061936 | 0.84 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL17061934 | 0.84 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL21354258 | 0.84 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL25215811 | 0.77 | GAA (0.38) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL2060839 | 0.77 | CHRNB2 (0.38) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL4052556 | 0.75 | — | — | |
| Acetic Acid SCHEMBL455505 | 0.74 | CHRNB2 (0.36) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL18152255 | 0.73 | CYP1A2 (0.40) | TSHRLMNAALOX15HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6693190-B1 | TETRAAZACYCLODODECANE MACROCYCLE DERIVATIVES INCLUDING METAL COMPLEXES; MAGNETIC RESONANCE IMAGING AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2004-02-17 | — | — | US | disclosed |
| EP-0708761-B1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INT BV (NL) | 2002-08-14 | — | — | EP | disclosed |
| WO-1995031444-A1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | H1-2, H1-0, H1-3 | TSHR 1230/4885LMNA 3012/4885ALOX15 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.